Terms ending in 2027
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,612,041 | An Isolated Activin-Binding Actriia Polypeptide Comprising the Seq Id No: 7 and Uses for Promoting Bone Growth In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 9,452,197 | Antagonists of BMP9, BMP10, ALK1 and Other ALK1 Ligands, and Uses Thereof In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 10,059,756 | Compositions Comprising ALK1-ECD Protein In force · High confidence | Ludwig Institute for Cancer Research Ltd. | In force | High confidence | |
| US 12,144,860 | ALK1 Receptor and Ligand Antagonists and Uses Thereof In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 7,833,971 | Uses of Cerberus, Coco and Derivatives Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 8,007,809 | Activin-Actrii Antagonists and Uses for Increasing Red Blood Cell Levels In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 8,895,016 | Antagonists of activin-actriia and uses for increasing red blood cell levels In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.